Vtama (tapinarof) cream, 1%, granted strong recommendation in the 2026 American Academy of Dermatology Guidelines for pediatric atopic dermatitis – Organon

Organon announced that Vtama cream was granted a strong, evidence-based recommendation by the American Academy of Dermatology (AAD) in their 2026 guidelines for the management and treatment of atopic dermatitis (AD) in pediatric patients, published on April 7, 2026. The guidelines name Vtama cream as the only steroid-free topical treatment the AAD found to be supported by a high certainty of evidence, that is indicated across all severities in children aged 2 years and older with AD. In the pivotal studies for VTAMA in AD, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.

The 2026 AAD pediatric atopic dermatitis guidelines are the first pediatric-specific AD guidelines issued by the AAD, and underscore important considerations for pediatric versus adult dermatological care. The pediatric guidelines provide evidence-based recommendations for topical therapies (prescription and non-prescription), phototherapy, and systemic therapies, ensuring the dermatology community has access to the best available data when developing prevention and treatments plans for pediatric patients.

“Following the strong recommendation VTAMA cream received in the 2025 AAD guidelines for adults with AD, we are thrilled to see VTAMA recognized in the newly released 2026 pediatric AD guidelines, especially as the only treatment with a high certainty of evidence and a strong recommendation for pediatric patients that is indicated across all disease severities,” said Rafael Chaves Cardona, Head of US Medical Affairs at Organon. “While patients with AD may share similarities across life stages, children and adolescents may have distinct treatment considerations compared with adults, such as safety and dosing, highlighting the need for clear, pediatric-specific guidance. These updated guidelines not only support clinicians and patients, but also help to provide caregivers with clear, evidence-based direction to help inform treatment discussions with their care team and confidently support those in their care. This AAD recommendation once again reinforces VTAMA cream as a steroid-free topical prescription option with just one strength, one formulation, and once-daily dosing that has no label restrictions on use based on disease severity, affected body surface area, or duration of use.”

The strong recommendation by the AAD for Vtama cream was supported by robust evidence from the Phase 3 pivotal trials, ADORING 1 and ADORING 2.